Citizens Financial Group Inc. RI acquired a new stake in Corteva, Inc. (NYSE:CTVA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,370 shares of the company's stock, valued at approximately $1,471,000.
Other large investors also recently bought and sold shares of the company. JPL Wealth Management LLC acquired a new position in shares of Corteva in the 3rd quarter worth approximately $25,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Corteva during the 4th quarter valued at approximately $27,000. Bank of Jackson Hole Trust bought a new position in Corteva during the fourth quarter worth $28,000. Cornerstone Financial Management LLC bought a new stake in Corteva during the fourth quarter valued at $29,000. Finally, Elevation Wealth Partners LLC raised its holdings in shares of Corteva by 334.6% during the second quarter. Elevation Wealth Partners LLC now owns 339 shares of the company's stock worth $29,000 after purchasing an additional 261 shares during the period. Institutional investors own 81.54% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on CTVA shares. Mizuho lifted their price target on shares of Corteva from $96.00 to $97.00 and gave the company an "outperform" rating in a report on Tuesday, July 14th. Citigroup raised their target price on shares of Corteva from $85.00 to $86.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. Jefferies Financial Group lifted their target price on Corteva from $95.00 to $97.00 in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $101.00 target price on shares of Corteva in a report on Monday, August 3rd. Finally, Weiss Ratings downgraded Corteva from a "hold (c+)" rating to a "hold (c)" rating in a report on Monday, August 3rd. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Corteva has an average rating of "Moderate Buy" and a consensus target price of $91.50.
View Our Latest Analysis on CTVA
Corteva Price Performance
Shares of NYSE:CTVA opened at $77.97 on Wednesday. The firm's 50 day moving average is $81.84 and its two-hundred day moving average is $80.12. Corteva, Inc. has a 52 week low of $60.53 and a 52 week high of $90.97. The firm has a market capitalization of $52.02 billion, a P/E ratio of 51.64, a PEG ratio of 2.35 and a beta of 0.57. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.07.
Corteva (NYSE:CTVA - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.06. The business had revenue of $6.38 billion during the quarter, compared to the consensus estimate of $6.60 billion. Corteva had a return on equity of 10.18% and a net margin of 5.66%.The business's revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.20 earnings per share. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. Analysts anticipate that Corteva, Inc. will post 3.72 earnings per share for the current year.
Corteva Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 1st. Corteva's payout ratio is 47.68%.
Corteva Profile
(
Free Report)
Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Corteva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corteva wasn't on the list.
While Corteva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.